Search

Your search keyword '"Espinola-Klein, C"' showing total 365 results
Start Over Author "Espinola-Klein, C"
365 results on '"Espinola-Klein, C"'

2. Risk factors for intensive care admission in pediatric patients with COVID-19 - results of the German na-tionwide inpatient sample

Author

Keller, K, primary, Sagoschen, I, additional, Schmitt, V H, additional, Sivanathan, V, additional, Farmakis, I T, additional, Hahad, O, additional, Koelmel, S, additional, Schmidt, F P, additional, Espinola-Klein, C, additional, Konstantinides, S, additional, Munzel, T, additional, Lurz, P, additional, and Hobohm, L, additional

Published
2024
Full Text
View/download PDF

5. Editor's Choice – Exercise Therapy for Chronic Symptomatic Peripheral Artery Disease: A Clinical Consensus Document of the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases in Collaboration With the European Society of Vascular Medicine and the European Society for Vascular Surgery

Author

Mazzolai, L, Belch, J, Venermo, M, Aboyans, V, Brodmann, M, Bura-Rivière, A, Debus, S, Espinola-Klein, C, Harwood, AE, Hawley, JA, Lanzi, S, Madarič, J, Mahé, G, Malatesta, D, Schlager, O, Schmidt-Trucksäss, A, Seenan, C, Sillesen, H, Tew, GA, Visonà, A, Mazzolai, L, Belch, J, Venermo, M, Aboyans, V, Brodmann, M, Bura-Rivière, A, Debus, S, Espinola-Klein, C, Harwood, AE, Hawley, JA, Lanzi, S, Madarič, J, Mahé, G, Malatesta, D, Schlager, O, Schmidt-Trucksäss, A, Seenan, C, Sillesen, H, Tew, GA, and Visonà, A

Abstract

All guidelines worldwide strongly recommend exercise as a pillar in the management of patients affected by lower extremity peripheral artery disease (PAD). Exercise therapy in this setting presents different modalities, and a structured programme provides optimal results. This clinical consensus paper is intended to promote and assist the set up of comprehensive exercise programmes and best advice for patients with symptomatic chronic PAD. Different exercise training protocols specific for patients with PAD are presented. Data on patient assessment and outcome measures are described based on the current best evidence. The document ends by highlighting supervised exercise programme access disparities across Europe and the evidence gaps requiring further research.

Published
2024

6. Editor's Choice – Recommendations for Registry Data Collection for Revascularisations of Acute Limb Ischaemia: A Delphi Consensus from the International Consortium of Vascular Registries

Author

Earnshaw, J., Mani, K., Acosta, S., Cochennec, F., Goncalves, F.B., van den, J.C., Diener, H., Rieß, H.C., Gottsäter, A., Hinchliffe, R., Jongkind, V., Koelemay, M., Menyhei, G., Svetlikov, A., Tshomba, Y., Venermo, M., Tulamo, R., Boyle, J.R., de Borst, G.J., Kolh, P., Dick, F., Bertges, D., Eldrup, N., Beck, A.W., Szeberin, Z., Beiles, B., Altreuther, M., Lopez-Espada, C., Aboyans, V., Ricco, J.-B., Espinola-Klein, C., Zeller, T., Schellong, S.M., Hoffmann, U., Twine, C.P., Ambler, G., Thomson, I., Behrendt, Christian-Alexander, Björck, Martin, Schwaneberg, Thea, Debus, Eike S., Cronenwett, Jack, and Sigvant, Birgitta

Published
2019
Full Text
View/download PDF

10. Diagnostik

Author

Lobmann, R., Espinola-Klein, C., Krämer, H.H., Schadmand-Fischer, S., Waldecker, U., Eckardt, A., Eckardt, Anke, editor, and Lobmann, Ralf, editor

Published
2015
Full Text
View/download PDF

12. Platelet responsiveness in the post-acute phase of pulmonary embolism

Author

von Ungern-Sternberg, S, additional, ten Cate, V, additional, Panova-Noeva, M, additional, Dahlen, B, additional, Prochaska, H J, additional, Heitmeier, S, additional, Gerdes, C, additional, Konstantinides, V S, additional, Münzel, T, additional, Espinola-Klein, C, additional, Lackner, J K, additional, ten Cate, H, additional, Leineweber, K, additional, Wild, S P, additional, and Jurk, K, additional

Published
2023
Full Text
View/download PDF

21. Chronic Venous Insufficiency, Cardiovascular Disease, and Mortality: A Population Study

Author

Prochaska, J.H., primary, Arnold, N., additional, Falcke, A., additional, Kopp, S., additional, Schulz, A., additional, Buch, G., additional, Moll, S., additional, Panova-Noeva, M., additional, Jünger, C., additional, Eggebrecht, L., additional, Pfeiffer, N., additional, Beutel, M., additional, Binder, H., additional, Grabbe, S., additional, Lackner, K.J., additional, Ten Cate-Hoek, A., additional, Espinola-Klein, C., additional, Münzel, T., additional, and Wild, P.S., additional

Published
2022
Full Text
View/download PDF

22. Exercise Therapy for Chronic Symptomatic Peripheral Artery Disease: A Clinical Consensus Document of the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases in Collaboration With the European Society of Vascular Medicine and the European Society for Vascular Surgery

Author

Mazzolai, L., Belch, J., Venermo, M., Aboyans, V., Brodmann, M., Bura-Rivière, A., Debus, S., Espinola-Klein, C., Harwood, A.E., Hawley, J.A., Lanzi, S., Madarič, J., Mahé, G., Malatesta, D., Schlager, O., Schmidt-Trucksäss, A., Seenan, C., Sillesen, H., Tew, G.A., and Visonà, A.

Published
2024
Full Text
View/download PDF

24. Chronic venous insufficiency, cardiovascular disease, and mortality: a population study

Author

Prochaska, J.H., Prochaska, J.H., Arnold, N., Falcke, A., Kopp, S., Schulz, A., Buch, G., Moll, S., Panova-Noeva, M., Junger, C., Eggebrecht, L., Pfeiffer, N., Beutel, M., Binder, H., Grabbe, S., Lackner, K.J., Ten Cate-Hoek, A., Espinola-Klein, C., Munzel, T., Wild, P.S., Prochaska, J.H., Prochaska, J.H., Arnold, N., Falcke, A., Kopp, S., Schulz, A., Buch, G., Moll, S., Panova-Noeva, M., Junger, C., Eggebrecht, L., Pfeiffer, N., Beutel, M., Binder, H., Grabbe, S., Lackner, K.J., Ten Cate-Hoek, A., Espinola-Klein, C., Munzel, T., and Wild, P.S.

Published
2021

30. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial

Author

Schmidtmann, I. (Irene), Ageno, W. (Walter), Bauersachs, R.M. (Rupert M.), Becattini, C. (Cecilia), Bernardi, E. (Enrico), Beyer-Westendorf, J. (Jan), Bonacchini, L. (Luca), Brachmann, J. (Johannes), Christ, M. (Michael), Czihal, M. (Michael), Duerschmied, D. (Daniel), Empen, K. (Klaus), Espinola-Klein, C. (Christine), Ficker, J.H. (Joachim H.), Fonseca, C. (Candida), Genth-Zotz, S. (Sabine), Jiménez, D. (David), Harjola, V.P. (Veli-Pekka), Held, M. (Matthias), Iogna-Prat, L. (Lorenzo), Lange, T.J. (Tobias J.), Manolis, A. (Athanasios), Meyer, A. (Andreas), Mustonen, P. (Pirjo), Rauch-Kroehnert, U. (Ursula), Ruiz-Artacho, P. (Pedro), Schellong, S. (Sebastian), Schwaiblmair, M. (Martin), Stahrenberg, R. (Raoul), Westerweel, P.E. (Peter), Wild, P.S. (Philipp S.), Konstantinides, S.V. (Stavros V.), and Lankeit, M. (Mareike)

Subjects
Rivaroxaban, Pulmonary embolism, Home treatment, Management trial, Right ventricular dysfunction, Risk stratification
Abstract

Aims To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban. Methods and results We conducted a prospective multicentre single-arm investigator initiated and academically sponsored management trial in patients with acute low-risk PE (EudraCT Identifier 2013-001657-28). Eligibility criteria included absence of (i) haemodynamic instability, (ii) right ventricular dysfunction or intracardiac thrombi, and (iii) serious comorbidities. Up to two nights of hospital stay were permitted. Rivaroxaban was given at the approved dose for PE for >_3 months. The primary outcome was symptomatic recurrent venous thromboembolism (VTE) or PE-related death within 3 months of enrolment. An interim analysis was planned after the first 525 patients, with prespecified early termination of the study if the null hypothesis could be rejected at the level of a = 0.004 (

Published
2020

38. Follow-up of Patients After Revascularisation for Peripheral Arterial Diseases: A Consensus Document From the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society of Vascular Surgery

Author

Venermo, M., primary, Sprynger, M., additional, Desormais, I., additional, Björck, M., additional, Brodmann, M., additional, Cohnert, T., additional, De Carlo, M., additional, Espinola-Klein, C., additional, Kownator, S., additional, Mazzolai, L., additional, Naylor, R., additional, Vlachopoulos, C., additional, Ricco, J.-B., additional, and Aboyans, V., additional

Published
2019
Full Text
View/download PDF

39. Edoxaban for the treatment of cancer-associated venous thromboembolism

Author

Raskob, GE, van Es, N, Verhamme, P, Carrier, M, Di Nisio, M, Garcia, D, Grosso, MA, Kakkar, AK, Kovacs, MJ, Mercuri, MF, Meyer, G, Segers, A, Shi, M, Wang, TF, Yeo, E, Zhang, G, Zwicker, JI, Weitz, JI, Büller, HR, Beyer-Westendorf, J, Boda, Z, Chlumsky, Y, Gibbs, H, Kamphuizen, PW, Monreal, M, Ockleford, P, Pabinger-Fasching, I, Sinnaeve, P, Beenen, L, Gerdes, V, Laleman, W, Larrey, D, van Mechelen, R, Roos, Y, Scheerder, M, Slagboom, T, Thijs, V, Eikelboom, JW, Crowther, M, Roberts, RS, Vanassche, T, Vandenbriele, C, Debaveye, B, Dani, V, Schwocho, L, Duggal, A, Baker, R, Carroll, P, Chan, N, Coughlin, P, Crispin, P, Gallus, A, Hugman, A, Tran, H, Brodmann, M, Mathies, R, Rossmann, D, Deeren, D, Hainaut, P, Jochmans, K, Vercauter, P, Wautrecht, JC, Champion, P, Gross, P, Lee, A, Shivakumar, S, Tagalakis, V, Zed, E, Kovarova, K, Lastuvka, J, Matoska, P, Prosecky, R, Achkar, A, Aquilanti, S, Chatellain, P, Cony-Makhoul, P, Del Piano, F, Elias, A, Falvo, N, Ferrari, E, Mahé, I, Merle, P, Mismetti, P, Muron, T, Pernod, G, Quere, I, Schmidt, J, Stephan, D, Espinola-Klein, C, Horacek, T, Kröning, R, Oettler, W, Schellong, S, Schön, N, Zwemmrich, C, Farkas, K, Gurzo, M, Nyirati, G, Pecsvarady, Z, Riba, M, Becattini, C, Cattaneo, M, Falanga, A, Ghirarduzzi, A, Imberti, D, Lodigiani, C, Parisi, R, Porreca, E, Squizzato, A, Tassoni, MI, Villalta, S, Visonà, A, Beeker, A, Boersma, W, Brouwer, R, Dees, A, Huisman, M, Kuijer, P, Mairuhu, R, Meijer, K, Middeldorp, S, Otten, HM, van Marwijk-Kooy, M, van Wissen, S, Westerweel, P, Harper, P, Merriman, E, Ockelford, P, Royle, G, Smith, M, Cereto Castro, F, de Oña Navarrete, R, Font Puig, C, Gallardo Díaz, E, Garcia-Bragado Dalmau, F, Ruiz Artacho, P, Santamaria, A, Baumann Kreuziger, L, De Sancho, M, Gaddh, M, Metjian, A, Rojas Hernandez, CM, Shah, V, Smith, W, Wun, T, Xiang, Z, Raskob, G, van Es, N, Verhamme, P, Carrier, M, Di Nisio, M, Garcia, D, Grosso, M, Kakkar, A, Kovacs, M, Mercuri, M, Meyer, G, Segers, A, Shi, M, Wang, T, Yeo, E, Zhang, G, Zwicker, J, Weitz, J, Büller, H, Beyer-Westendorf, J, Boda, Z, Chlumsky, Y, Gibbs, H, Kamphuizen, P, Monreal, M, Ockleford, P, Pabinger-Fasching, I, Sinnaeve, P, Beenen, L, Gerdes, V, Laleman, W, Larrey, D, van Mechelen, R, Roos, Y, Scheerder, M, Slagboom, T, Thijs, V, Eikelboom, J, Crowther, M, Roberts, R, Vanassche, T, Vandenbriele, C, Debaveye, B, Dani, V, Schwocho, L, Duggal, A, Baker, R, Carroll, P, Chan, N, Coughlin, P, Crispin, P, Gallus, A, Hugman, A, Tran, H, Brodmann, M, Mathies, R, Rossmann, D, Deeren, D, Hainaut, P, Jochmans, K, Vercauter, P, Wautrecht, J, Champion, P, Gross, P, Lee, A, Shivakumar, S, Tagalakis, V, Zed, E, Kovarova, K, Lastuvka, J, Matoska, P, Prosecky, R, Achkar, A, Aquilanti, S, Chatellain, P, Cony-Makhoul, P, Del Piano, F, Elias, A, Falvo, N, Ferrari, E, Mahé, I, Merle, P, Mismetti, P, Muron, T, Pernod, G, Quere, I, Schmidt, J, Stephan, D, Espinola-Klein, C, Horacek, T, Kröning, R, Oettler, W, Schellong, S, Schön, N, Zwemmrich, C, Farkas, K, Gurzo, M, Nyirati, G, Pecsvarady, Z, Riba, M, Becattini, C, Cattaneo, M, Falanga, A, Ghirarduzzi, A, Imberti, D, Lodigiani, C, Parisi, R, Porreca, E, Squizzato, A, Tassoni, M, Villalta, S, Visonà, A, Beeker, A, Boersma, W, Brouwer, R, Dees, A, Huisman, M, Kuijer, P, Mairuhu, R, Meijer, K, Middeldorp, S, Otten, H, van Marwijk-Kooy, M, van Wissen, S, Westerweel, P, Harper, P, Merriman, E, Ockelford, P, Royle, G, Smith, M, Cereto Castro, F, de Oña Navarrete, R, Font Puig, C, Gallardo Díaz, E, Garcia-Bragado Dalmau, F, Ruiz Artacho, P, Santamaria, A, Baumann Kreuziger, L, De Sancho, M, Gaddh, M, Metjian, A, Rojas Hernandez, C, Shah, V, Smith, W, Wun, T, Xiang, Z, Graduate School, CCA - Cancer Treatment and Quality of Life, Vascular Medicine, ACS - Amsterdam Cardiovascular Sciences, ANS - Neurovascular Disorders, Radiology and Nuclear Medicine, Other Research, Other departments, Neurology, APH - Societal Participation & Health, APH - Quality of Care, Coronel Institute of Occupational Health, ARD - Amsterdam Reproduction and Development, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, ACS - Atherosclerosis & ischemic syndromes, ACS - Pulmonary hypertension & thrombosis, and ACS - Microcirculation

Subjects
Adult, Dalteparin, Male, Randomization, Pyridines, Hemorrhage, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, Recurrence, law, Edoxaban, Neoplasms, medicine, Humans, Aged, Intention-to-treat analysis, Heparin, business.industry, Standard treatment, Low-Molecular-Weight, Anticoagulants, Cancer, Follow-Up Studies, Heparin, Low-Molecular-Weight, Intention to Treat Analysis, Middle Aged, Thiazoles, Venous Thromboembolism, General Medicine, medicine.disease, Thrombosis, chemistry, 030220 oncology & carcinogenesis, Anesthesia, Venous Thromboembolism, cancer, thrombosis, business, medicine.drug
Abstract

BACKGROUND Low-molecular-weight heparin is the standard treatment for cancer-associated venous thromboembolism. The role of treatment with direct oral anticoagulant agents is unclear. METHODS In this open-label, noninferiority trial, we randomly assigned patients with cancer who had acute symptomatic or incidental venous thromboembolism to receive either low-molecular-weight heparin for at least 5 days followed by oral edoxaban at a dose of 60 mg once daily (edoxaban group) or subcutaneous dalteparin at a dose of 200 IU per kilogram of body weight once daily for 1 month followed by dalteparin at a dose of 150 IU per kilogram once daily (dalteparin group). Treatment was given for at least 6 months and up to 12 months. The primary outcome was a composite of recurrent venous thromboembolism or major bleeding during the 12 months after randomization, regardless of treatment duration. RESULTS Of the 1050 patients who underwent randomization, 1046 were included in the modified intention-to-treat analysis. A primary-outcome event occurred in 67 of the 522 patients (12.8%) in the edoxaban group as compared with 71 of the 524 patients (13.5%) in the dalteparin group (hazard ratio, 0.97; 95% confidence interval [CI], 0.70 to 1.36; P = 0.006 for noninferiority; P = 0.87 for superiority). Recurrent venous thromboembolism occurred in 41 patients (7.9%) in the edoxaban group and in 59 patients (11.3%) in the dalteparin group (difference in risk, -3.4 percentage points; 95% CI, -7.0 to 0.2). Major bleeding occurred in 36 patients (6.9%) in the edoxaban group and in 21 patients (4.0%) in the dalteparin group (difference in risk, 2.9 percentage points; 95% CI, 0.1 to 5.6). CONCLUSIONS Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding. The rate of recurrent venous thromboembolism was lower but the rate of major bleeding was higher with edoxaban than with dalteparin. (Funded by Daiichi Sankyo; Hokusai VTE Cancer ClinicalTrials. gov number, NCT02073682.)

Published
2018

40. Correction: Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration (PLoS One (2018) 13:4 (e0191172) DOI: 10.1371/journal.pone.0191172)

Author

Lorenz M. W., Gao L., Ziegelbauer K., Norata G. D., Empana J. P., Schmidtmann I., Lin H. -J., McLachlan S., Bokemark L., Ronkainen K., Amato M., Schminke U., Srinivasan S. R., Lind L., Okazaki S., Stehouwer C. D. A., Willeit P., Polak J. F., Steinmetz H., Sander D., Poppert H., Desvarieux M., Arfan Ikram M., Johnsen S. H., Staub D., Sirtori C. R., Iglseder B., Beloqui O., Engstrom G., Friera A., Rozza F., Xie W., Parraga G., Grigore L., Plichart M., Blankenberg S., Su T. -C., Schmidt C., Tuomainen T. -P., Veglia F., Volzke H., Nijpels G., Willeit J., Sacco R. L., Franco O. H., Uthoff H., Hedblad B., Suarez C., Izzo R., Zhao D., Wannarong T., Catapano A., Ducimetiere P., Espinola-Klein C., Chien K. -L., Price J. F., Bergstrom G., Kauhanen J., Tremoli E., Dorr M., Berenson G., Kitagawa K., Dekker J. M., Kiechl S., Sitzer M., Bickel H., Rundek T., Hofman A., Mathiesen E. B., Castelnuovo S., Landecho M. F., Rosvall M., Gabriel R., De Luca N., Liu J., Baldassarre D., Kavousi M., De Groot E., Bots M. L., Yanez D. N., Thompson S. G., Lorenz, M. W., Gao, L., Ziegelbauer, K., Norata, G. D., Empana, J. P., Schmidtmann, I., Lin, H. -J., Mclachlan, S., Bokemark, L., Ronkainen, K., Amato, M., Schminke, U., Srinivasan, S. R., Lind, L., Okazaki, S., Stehouwer, C. D. A., Willeit, P., Polak, J. F., Steinmetz, H., Sander, D., Poppert, H., Desvarieux, M., Arfan Ikram, M., Johnsen, S. H., Staub, D., Sirtori, C. R., Iglseder, B., Beloqui, O., Engstrom, G., Friera, A., Rozza, F., Xie, W., Parraga, G., Grigore, L., Plichart, M., Blankenberg, S., Su, T. -C., Schmidt, C., Tuomainen, T. -P., Veglia, F., Volzke, H., Nijpels, G., Willeit, J., Sacco, R. L., Franco, O. H., Uthoff, H., Hedblad, B., Suarez, C., Izzo, R., Zhao, D., Wannarong, T., Catapano, A., Ducimetiere, P., Espinola-Klein, C., Chien, K. -L., Price, J. F., Bergstrom, G., Kauhanen, J., Tremoli, E., Dorr, M., Berenson, G., Kitagawa, K., Dekker, J. M., Kiechl, S., Sitzer, M., Bickel, H., Rundek, T., Hofman, A., Mathiesen, E. B., Castelnuovo, S., Landecho, M. F., Rosvall, M., Gabriel, R., De Luca, N., Liu, J., Baldassarre, D., Kavousi, M., De Groot, E., Bots, M. L., Yanez, D. N., and Thompson, S. G.

Abstract

An affiliation for Moise Desvarieux is missing. In addition to affiliation #22, Moise Desvarieux is affiliated with: METHODS Core, Centre de Recherche Epidémiologie et Statistique Paris Sorbonne Cité (CRESS), Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1153, Paris France.

Published
2018

43. Editor's Choice – Recommendations for Registry Data Collection for Revascularisations of Acute Limb Ischaemia: A Delphi Consensus from the International Consortium of Vascular Registries

Author

Behrendt, C. -A., Bjorck, M., Schwaneberg, T., Debus, E. S., Cronenwett, J., Sigvant, B., Earnshaw, J., Mani, K., Acosta, S., Cochennec, F., Goncalves, F. B., van den, J. C., Diener, H., Riess, H. C., Gottsater, A., Hinchliffe, R., Jongkind, V., Koelemay, M., Menyhei, G., Svetlikov, A., Tshomba, Y., Venermo, M., Tulamo, R., Boyle, J. R., de Borst, G. J., Kolh, P., Dick, F., Bertges, D., Eldrup, N., Beck, A. W., Szeberin, Z., Beiles, B., Altreuther, M., Lopez-Espada, C., Aboyans, V., Ricco, J. -B., Espinola-Klein, C., Zeller, T., Schellong, S. M., Hoffmann, U., Twine, C. P., Ambler, G., Thomson, I., Tshomba Y. (ORCID:0000-0001-7304-7553), Behrendt, C. -A., Bjorck, M., Schwaneberg, T., Debus, E. S., Cronenwett, J., Sigvant, B., Earnshaw, J., Mani, K., Acosta, S., Cochennec, F., Goncalves, F. B., van den, J. C., Diener, H., Riess, H. C., Gottsater, A., Hinchliffe, R., Jongkind, V., Koelemay, M., Menyhei, G., Svetlikov, A., Tshomba, Y., Venermo, M., Tulamo, R., Boyle, J. R., de Borst, G. J., Kolh, P., Dick, F., Bertges, D., Eldrup, N., Beck, A. W., Szeberin, Z., Beiles, B., Altreuther, M., Lopez-Espada, C., Aboyans, V., Ricco, J. -B., Espinola-Klein, C., Zeller, T., Schellong, S. M., Hoffmann, U., Twine, C. P., Ambler, G., Thomson, I., and Tshomba Y. (ORCID:0000-0001-7304-7553)

Abstract

Objective: To develop a minimum core data set for evaluation of acute limb ischaemia (ALI) revascularisation treatment and outcomes that would enable collaboration among international registries. Methods: A modified Delphi approach was used to achieve consensus among international multidisciplinary vascular specialists and registry members of the International Consortium of Vascular Registries (ICVR). Variables identified in the literature or suggested by the expert panel, and variables, including definitions, currently used in 15 countries in the ICVR, were assessed to define both a minimum core and an optimum data set to register ALI treatment. Clinical relevance and practicability were both assessed, and consensus was defined as ≥ 80% agreement among participants. Results: Of 40 invited experts, 37 completed a preliminary survey and 31 completed the two subsequent Delphi rounds via internet exchange and face to face discussions. In total, 117 different items were generated from the various registry data forms, an extensive review of the literature, and additional suggestions from the experts, for potential inclusion in the data set. Ultimately, 35 items were recommended for inclusion in the minimum core data set, including 23 core items important for all registries, and an additional 12 more specific items for registries capable of capturing more detail. These 35 items supplement previous data elements recommended for registering chronic peripheral arterial occlusive disease treatment. Conclusion: A modified Delphi study allowed 37 international vascular registry experts to achieve a consensus recommendation for a minimum core and an optimum data set for registries covering patients who undergo ALI revascularisation. Continued global harmonisation of registry infrastructure and definition of items allows international comparisons and global quality improvement. Furthermore, it can help to define and monitor standards of care and enable international research coll

Published
2019

45. Editor's Choice – Recommendations for Registry Data Collection for Revascularisations of Acute Limb Ischaemia: A Delphi Consensus from the International Consortium of Vascular Registries

Author

Behrendt, Christian-Alexander, primary, Björck, Martin, additional, Schwaneberg, Thea, additional, Debus, Eike S., additional, Cronenwett, Jack, additional, Sigvant, Birgitta, additional, Earnshaw, J., additional, Mani, K., additional, Acosta, S., additional, Cochennec, F., additional, Goncalves, F.B., additional, van den, J.C., additional, Diener, H., additional, Rieß, H.C., additional, Gottsäter, A., additional, Hinchliffe, R., additional, Jongkind, V., additional, Koelemay, M., additional, Menyhei, G., additional, Svetlikov, A., additional, Tshomba, Y., additional, Venermo, M., additional, Tulamo, R., additional, Boyle, J.R., additional, de Borst, G.J., additional, Kolh, P., additional, Dick, F., additional, Bertges, D., additional, Eldrup, N., additional, Beck, A.W., additional, Szeberin, Z., additional, Beiles, B., additional, Altreuther, M., additional, Lopez-Espada, C., additional, Aboyans, V., additional, Ricco, J.-B., additional, Espinola-Klein, C., additional, Zeller, T., additional, Schellong, S.M., additional, Hoffmann, U., additional, Twine, C.P., additional, Ambler, G., additional, and Thomson, I., additional

Published
2019
Full Text
View/download PDF

46. Edoxaban for the treatment of cancer-associated venous thromboembolism

Author

Raskob, G, van Es, N, Verhamme, P, Carrier, M, Di Nisio, M, Garcia, D, Grosso, M, Kakkar, A, Kovacs, M, Mercuri, M, Meyer, G, Segers, A, Shi, M, Wang, T, Yeo, E, Zhang, G, Zwicker, J, Weitz, J, Büller, H, Beyer-Westendorf, J, Boda, Z, Chlumsky, Y, Gibbs, H, Kamphuizen, P, Monreal, M, Ockleford, P, Pabinger-Fasching, I, Sinnaeve, P, Beenen, L, Gerdes, V, Laleman, W, Larrey, D, van Mechelen, R, Roos, Y, Scheerder, M, Slagboom, T, Thijs, V, Eikelboom, J, Crowther, M, Roberts, R, Vanassche, T, Vandenbriele, C, Debaveye, B, Dani, V, Schwocho, L, Duggal, A, Baker, R, Carroll, P, Chan, N, Coughlin, P, Crispin, P, Gallus, A, Hugman, A, Tran, H, Brodmann, M, Mathies, R, Rossmann, D, Deeren, D, Hainaut, P, Jochmans, K, Vercauter, P, Wautrecht, J, Champion, P, Gross, P, Lee, A, Shivakumar, S, Tagalakis, V, Zed, E, Kovarova, K, Lastuvka, J, Matoska, P, Prosecky, R, Achkar, A, Aquilanti, S, Chatellain, P, Cony-Makhoul, P, Del Piano, F, Elias, A, Falvo, N, Ferrari, E, Mahé, I, Merle, P, Mismetti, P, Muron, T, Pernod, G, Quere, I, Schmidt, J, Stephan, D, Espinola-Klein, C, Horacek, T, Kröning, R, Oettler, W, Schellong, S, Schön, N, Zwemmrich, C, Farkas, K, Gurzo, M, Nyirati, G, Pecsvarady, Z, Riba, M, Becattini, C, Cattaneo, M, Falanga, A, Ghirarduzzi, A, Imberti, D, Lodigiani, C, Parisi, R, Porreca, E, Squizzato, A, Tassoni, M, Villalta, S, Visonà, A, Beeker, A, Boersma, W, Brouwer, R, Dees, A, Huisman, M, Kuijer, P, Mairuhu, R, Meijer, K, Middeldorp, S, Otten, H, van Marwijk-Kooy, M, van Wissen, S, Westerweel, P, Harper, P, Merriman, E, Ockelford, P, Royle, G, Smith, M, Cereto Castro, F, de Oña Navarrete, R, Font Puig, C, Gallardo Díaz, E, Garcia-Bragado Dalmau, F, Ruiz Artacho, P, Santamaria, A, Baumann Kreuziger, L, De Sancho, M, Gaddh, M, Metjian, A, Rojas Hernandez, C, Shah, V, Smith, W, Wun, T, Xiang, Z, Raskob, GE, Grosso, MA, Kakkar, AK, Kovacs, MJ, Mercuri, MF, Wang, TF, Zwicker, JI, Weitz, JI, Büller, HR, Kamphuizen, PW, Eikelboom, JW, Roberts, RS, Wautrecht, JC, Tassoni, MI, Otten, HM, Rojas Hernandez, CM, Raskob, G, van Es, N, Verhamme, P, Carrier, M, Di Nisio, M, Garcia, D, Grosso, M, Kakkar, A, Kovacs, M, Mercuri, M, Meyer, G, Segers, A, Shi, M, Wang, T, Yeo, E, Zhang, G, Zwicker, J, Weitz, J, Büller, H, Beyer-Westendorf, J, Boda, Z, Chlumsky, Y, Gibbs, H, Kamphuizen, P, Monreal, M, Ockleford, P, Pabinger-Fasching, I, Sinnaeve, P, Beenen, L, Gerdes, V, Laleman, W, Larrey, D, van Mechelen, R, Roos, Y, Scheerder, M, Slagboom, T, Thijs, V, Eikelboom, J, Crowther, M, Roberts, R, Vanassche, T, Vandenbriele, C, Debaveye, B, Dani, V, Schwocho, L, Duggal, A, Baker, R, Carroll, P, Chan, N, Coughlin, P, Crispin, P, Gallus, A, Hugman, A, Tran, H, Brodmann, M, Mathies, R, Rossmann, D, Deeren, D, Hainaut, P, Jochmans, K, Vercauter, P, Wautrecht, J, Champion, P, Gross, P, Lee, A, Shivakumar, S, Tagalakis, V, Zed, E, Kovarova, K, Lastuvka, J, Matoska, P, Prosecky, R, Achkar, A, Aquilanti, S, Chatellain, P, Cony-Makhoul, P, Del Piano, F, Elias, A, Falvo, N, Ferrari, E, Mahé, I, Merle, P, Mismetti, P, Muron, T, Pernod, G, Quere, I, Schmidt, J, Stephan, D, Espinola-Klein, C, Horacek, T, Kröning, R, Oettler, W, Schellong, S, Schön, N, Zwemmrich, C, Farkas, K, Gurzo, M, Nyirati, G, Pecsvarady, Z, Riba, M, Becattini, C, Cattaneo, M, Falanga, A, Ghirarduzzi, A, Imberti, D, Lodigiani, C, Parisi, R, Porreca, E, Squizzato, A, Tassoni, M, Villalta, S, Visonà, A, Beeker, A, Boersma, W, Brouwer, R, Dees, A, Huisman, M, Kuijer, P, Mairuhu, R, Meijer, K, Middeldorp, S, Otten, H, van Marwijk-Kooy, M, van Wissen, S, Westerweel, P, Harper, P, Merriman, E, Ockelford, P, Royle, G, Smith, M, Cereto Castro, F, de Oña Navarrete, R, Font Puig, C, Gallardo Díaz, E, Garcia-Bragado Dalmau, F, Ruiz Artacho, P, Santamaria, A, Baumann Kreuziger, L, De Sancho, M, Gaddh, M, Metjian, A, Rojas Hernandez, C, Shah, V, Smith, W, Wun, T, Xiang, Z, Raskob, GE, Grosso, MA, Kakkar, AK, Kovacs, MJ, Mercuri, MF, Wang, TF, Zwicker, JI, Weitz, JI, Büller, HR, Kamphuizen, PW, Eikelboom, JW, Roberts, RS, Wautrecht, JC, Tassoni, MI, Otten, HM, and Rojas Hernandez, CM

Abstract

BACKGROUND: Low-molecular-weight heparin is the standard treatment for cancer-associated venous thromboembolism. The role of treatment with direct oral anticoagulant agents is unclear. METHODS: In this open-label, noninferiority trial, we randomly assigned patients with cancer who had acute symptomatic or incidental venous thromboembolism to receive either low-molecular-weight heparin for at least 5 days followed by oral edoxaban at a dose of 60 mg once daily (edoxaban group) or subcutaneous dalteparin at a dose of 200 IU per kilogram of body weight once daily for 1 month followed by dalteparin at a dose of 150 IU per kilogram once daily (dalteparin group). Treatment was given for at least 6 months and up to 12 months. The primary outcome was a composite of recurrent venous thromboembolism or major bleeding during the 12 months after randomization, regardless of treatment duration. RESULTS: Of the 1050 patients who underwent randomization, 1046 were included in the modified intention-to-treat analysis. A primary-outcome event occurred in 67 of the 522 patients (12.8%) in the edoxaban group as compared with 71 of the 524 patients (13.5%) in the dalteparin group (hazard ratio, 0.97; 95% confidence interval [CI], 0.70 to 1.36; P = 0.006 for noninferiority; P = 0.87 for superiority). Recurrent venous thromboembolism occurred in 41 patients (7.9%) in the edoxaban group and in 59 patients (11.3%) in the dalteparin group (difference in risk,-3.4 percentage points; 95% CI,-7.0 to 0.2). Major bleeding occurred in 36 patients (6.9%) in the edoxaban group and in 21 patients (4.0%) in the dalteparin group (difference in risk, 2.9 percentage points; 95% CI, 0.1 to 5.6). CONCLUSIONS: Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding. The rate of recurrent venous thromboembolism was lower but the rate of major bleeding was higher with edoxaban than with dalteparin.

Published
2018

47. Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration

Author

Lorenz, MW, Gao, L, Ziegelbauer, K, Norata, GD, Empana, JP, Schmidtmann, I, Lin, H J, McLachlan, S, Bokemark, L, Ronkainen, K, Amato, M, Schminke, U, Srinivasan, SR (Sathanur), Lind, L, Okazaki, S, Stehouwer, CDA, Willeit, P, Polak, JF, Steinmetz, H, Sander, D, Poppert, H, Desvarieux, M, Ikram, Arfan, Johnsen, SH, Staub, D, Sirtori, CR, Igiseder, B, Beloqui, O, Engstrom, G, Friera, A, Rozza, F, Xie, WX, Parraga, G, Grigore, L, Plichart, M, Blankenberg, S, Su, T C, Schmidt, C, Tuomainen, TP, Veglia, F, Volzke, H, Nijpels, G, Willeit, J, Sacco, RL, Franco Duran, OH, Uthoff, H, Hedblad, B, Suarez, C, Izzo, R, Zhao, D (Dan), Wannarong, T, Catapano, A, Ducimetiere, P, Espinola-Klein, C, Chien, K L, Price, JF, Bergstrom, G, Kauhanen, J, Tremoli, E, Dorr, M, Berenson, G, Kitagawa, K, Dekker, JM, Kiechl, S, Sitzer, M, Bickel, H, Rundek, T, Hofman, Bert, Mathiesen, EB, Castelnuovo, S, Landecho, MF, Rosvall, M, Gabriel, R, Luca, N, Liu, J, Baldassarre, D, Kavousi, Maryam, de Groot, E, Bots, ML, Yanez, D N, Lorenz, MW, Gao, L, Ziegelbauer, K, Norata, GD, Empana, JP, Schmidtmann, I, Lin, H J, McLachlan, S, Bokemark, L, Ronkainen, K, Amato, M, Schminke, U, Srinivasan, SR (Sathanur), Lind, L, Okazaki, S, Stehouwer, CDA, Willeit, P, Polak, JF, Steinmetz, H, Sander, D, Poppert, H, Desvarieux, M, Ikram, Arfan, Johnsen, SH, Staub, D, Sirtori, CR, Igiseder, B, Beloqui, O, Engstrom, G, Friera, A, Rozza, F, Xie, WX, Parraga, G, Grigore, L, Plichart, M, Blankenberg, S, Su, T C, Schmidt, C, Tuomainen, TP, Veglia, F, Volzke, H, Nijpels, G, Willeit, J, Sacco, RL, Franco Duran, OH, Uthoff, H, Hedblad, B, Suarez, C, Izzo, R, Zhao, D (Dan), Wannarong, T, Catapano, A, Ducimetiere, P, Espinola-Klein, C, Chien, K L, Price, JF, Bergstrom, G, Kauhanen, J, Tremoli, E, Dorr, M, Berenson, G, Kitagawa, K, Dekker, JM, Kiechl, S, Sitzer, M, Bickel, H, Rundek, T, Hofman, Bert, Mathiesen, EB, Castelnuovo, S, Landecho, MF, Rosvall, M, Gabriel, R, Luca, N, Liu, J, Baldassarre, D, Kavousi, Maryam, de Groot, E, Bots, ML, and Yanez, D N

Published
2018

48. Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk – Results from the PROG-IMT collaboration

Author

Lorenz, M., Gao, L., Ziegelbauer, K., Norata, Giuseppe, Empana, J., Schmidtmann, I., Lin, H., McLachlan, S., Bokemark, L., Ronkainen, K., Amato, M., Schminke, U., Srinivasan, S., Lind, L., Okazaki, S., Stehouwer, C., Willeit, P., Polak, J., Steinmetz, H., Sander, D., Poppert, H., Desvarieux, M., Arfan Ikram, M., Johnsen, S., Staub, D., Sirtori, C., Iglseder, B., Beloqui, O., Engström, G., Friera, A., Rozza, F., Xie, W., Parraga, G., Grigore, L., Plichart, M., Blankenberg, S., Su, T., Schmidt, C., Tuomainen, T., Veglia, F., Völzke, H., Nijpels, G., Willeit, J., Sacco, R., Franco, O., Uthoff, H., Hedblad, B., Suarez, C., Izzo, R., Zhao, D., Wannarong, T., Catapano, A., Ducimetiere, P., Espinola-Klein, C., Chien, K., Price, J., Bergström, G., Kauhanen, J., Tremoli, E., Dörr, M., Berenson, G., Kitagawa, K., Dekker, J., Kiechl, S., Sitzer, M., Bickel, H., Rundek, T., Hofman, A., Mathiesen, E., Castelnuovo, S., Landecho, M., Rosvall, M., Gabriel, R., de Luca, N., Liu, J., Baldassarre, D., Kavousi, M., de Groot, E., Bots, M., Yanez, D., Thompson, S., Lorenz, M., Gao, L., Ziegelbauer, K., Norata, Giuseppe, Empana, J., Schmidtmann, I., Lin, H., McLachlan, S., Bokemark, L., Ronkainen, K., Amato, M., Schminke, U., Srinivasan, S., Lind, L., Okazaki, S., Stehouwer, C., Willeit, P., Polak, J., Steinmetz, H., Sander, D., Poppert, H., Desvarieux, M., Arfan Ikram, M., Johnsen, S., Staub, D., Sirtori, C., Iglseder, B., Beloqui, O., Engström, G., Friera, A., Rozza, F., Xie, W., Parraga, G., Grigore, L., Plichart, M., Blankenberg, S., Su, T., Schmidt, C., Tuomainen, T., Veglia, F., Völzke, H., Nijpels, G., Willeit, J., Sacco, R., Franco, O., Uthoff, H., Hedblad, B., Suarez, C., Izzo, R., Zhao, D., Wannarong, T., Catapano, A., Ducimetiere, P., Espinola-Klein, C., Chien, K., Price, J., Bergström, G., Kauhanen, J., Tremoli, E., Dörr, M., Berenson, G., Kitagawa, K., Dekker, J., Kiechl, S., Sitzer, M., Bickel, H., Rundek, T., Hofman, A., Mathiesen, E., Castelnuovo, S., Landecho, M., Rosvall, M., Gabriel, R., de Luca, N., Liu, J., Baldassarre, D., Kavousi, M., de Groot, E., Bots, M., Yanez, D., and Thompson, S.

Abstract

Aims: Carotid intima media thickness (CIMT) predicts cardiovascular (CVD) events, but the predictive value of CIMT change is debated. We assessed the relation between CIMT change and events in individuals at high cardiovascular risk. Methods and results: From 31 cohorts with two CIMT scans (total n = 89070) on average 3.6 years apart and clinical follow-up, subcohorts were drawn: (A) individuals with at least 3 cardiovascular risk factors without previous CVD events, (B) individuals with carotid plaques without previous CVD events, and (C) individuals with previous CVD events. Cox regression models were fit to estimate the hazard ratio (HR) of the combined endpoint (myocardial infarction, stroke or vascular death) per standard deviation (SD) of CIMT change, adjusted for CVD risk factors. These HRs were pooled across studies. In groups A, B and C we observed 3483, 2845 and 1165 endpoint events, respectively. Average common CIMT was 0.79mm (SD 0.16mm), and annual common CIMT change was 0.01mm (SD 0.07mm), both in group A. The pooled HR per SD of annual common CIMT change (0.02 to 0.43mm) was 0.99 (95% confidence interval: 0.95–1.02) in group A, 0.98 (0.93–1.04) in group B, and 0.95 (0.89–1.04) in group C. The HR per SD of common CIMT (average of the first and the second CIMT scan, 0.09 to 0.75mm) was 1.15 (1.07–1.23) in group A, 1.13 (1.05–1.22) in group B, and 1.12 (1.05–1.20) in group C. Conclusions: We confirm that common CIMT is associated with future CVD events in individuals at high risk. CIMT change does not relate to future event risk in high-risk individuals.

Published
2018

49. Vaskuläre Summer School – ein Projekt der Jungen Angiologen zur Vermittlung gefäßmedizinischer Kompetenzen

Author

Freisinger, E, Krabbe, B, Czihal, M, Lindhoff-Last, E, Espinola-Klein, C, and Forum Junge Angiologen der DGA

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Zielsetzung: Vor dem Hintergrund der gegenwärtigen demographischen Entwicklung einer alternden Bevölkerung mit deutlichem Anstieg gefäßmedizinischer Patienten [ref:1] besteht ein steigender Bedarf an (Fach-)ÄrztInnen in der Gefäßmedizin zur Deckung der Gesundheitsversorgung.[zum vollständigen Text gelangen Sie über die oben angegebene URL], Gemeinsame Jahrestagung der Gesellschaft für Medizinische Ausbildung (GMA) und des Arbeitskreises zur Weiterentwicklung der Lehre in der Zahnmedizin (AKWLZ)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results